Eyebiotech (EyeBio) has dosed the first participants with diabetic macular oedema (DME) and neovascular age-related macular degeneration (NVAMD) in a Phase Ib/II clinical trial of intravitreal (IVT) Restoret (EYE103), a tri-specific Wnt agonist antibody.

The two-part, multi-centre study is titled ‘Anti-permeability Mechanism and Age-Related Ocular Neovascularization Evaluation (AMARONE).’

It includes an open-label multiple-ascending dose (MAD) study to assess the safety of Restoret and a single-masked, dose-finding study to compare the safety and preliminary efficacy of the therapy in NVAMD and DME participants.

Restoret will be administered to up to 92 subjects as part of a 12-week regimen.

Safety and mean change in best-corrected visual acuity (BCVA) from baseline to week 12 are the primary endpoints.

EyeBio chief scientific officer Tony Adamis said: “Restoret has the potential to address a major unmet need in these diseases, namely excess fluid in the retina.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“Anti-VEGF registrational trials and real-world data both show that excess fluid leads to poorer vision, and the longer that fluid resides in the retina, the less opportunity there is to recover vision.

“Restoret addresses a new biology, which is critical if we want to deliver results beyond those seen with anti-VEGF alone.”

The first participants dosed in the study were treated by Mark Barakat of Retinal Consultants of Arizona and J Edward Ysasaga of Southwest Retina Specialists.

EyeBio chief medical officer Jonathan Prenner said: “More than 60% of patients have suboptimal outcomes and more than 30%have active disease despite treatment with anti-VEGF agents.

“Restoret may present an opportunity to break through the efficacy ceiling we have reached with an anti-VEGF standard of care.”